Literature DB >> 17715634

Endoscopic retrogade cholangiopancreatography is safe and effective method for diagnosis and treatment of biliary and pancreatic disorders in octogenarians.

K C Thomopoulos1, K Vagenas, S F Assimakopoulos, C Giannikoulis, V Arvaniti, N Pagoni, V N Nikolopoulou.   

Abstract

BACKGROUND AND AIM: Diagnosis and treatment of pancreatic and biliary diseases represents a special problem in old patients who often suffer from one or more concomitant diseases. The aim of this study was to evaluate the safety and efficacy of ERCP in very old patients (octogenarians). PATIENTS AND METHODS: Patients 80 years or older who underwent ERCP from October 2001 to December 2005 were studied retrospectively.
RESULTS: A total of 209 patients (121 women, 88 men), with a mean age 86 +/- 4.4 years old (80-102) underwent 251 ERCPs. All but three patients tolerated the procedure well. Three procedures were not completed due to patients' discomfort (1.4%). Two of these patients underwent percutaneous transhepatic cholangiography and the other one was treated conservatively. A cholangiogram was obtained in 193 cases (92.3%), although in 7 patients an additional attempt was required. The main endoscopic findings were common bile duct stones in 51.8% (100/193) and cancer in 28% (54/193) of patients. Based on the diagnostic findings, a therapeutic intervention was indicated in 189 patients (90.4%) and was achieved in 181 of them (95.8%). Complications were observed in 9.6% of ERCPs (24/251). Post - ERCP mild pancreatitis was the more frequent complication in 11 procedures (4.4%). No severe pancreatitis was observed. Six procedures were complicated by cholangitis (2.4%) and two by cholecystitis (0.8%). Early surgical intervention was required in 2 cases because of oesophageal perforation and retroperitoneal perforation respectively. Two patients died (0.8%); one patient with pancreatic cancer died due to septic shock after inadequate biliary drainage and the other one died after operation for retroperitoneal perforation.
CONCLUSIONS: In conclusion, ERCP is safe and effective method for diagnosis and treatment of biliary and pancreatic disorders in octogenarians despite the high comorbidity in this group of patients.

Entities:  

Mesh:

Year:  2007        PMID: 17715634

Source DB:  PubMed          Journal:  Acta Gastroenterol Belg        ISSN: 1784-3227            Impact factor:   1.316


  6 in total

1.  A rare etiology of post-endoscopic retrograde cholangiopancreatography pneumoperitoneum.

Authors:  Stelios-F Assimakopoulos; Konstantinos-C Thomopoulos; Sofia Giali; Christos Triantos; Dimitrios Siagris; Charalambos Gogos
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

2.  Adverse events in older patients undergoing ERCP: a systematic review and meta-analysis.

Authors:  Lukejohn W Day; Lisa Lin; Ma Somsouk
Journal:  Endosc Int Open       Date:  2014-03-07

3.  Safety of endoscopic retrograde cholangiopancreatography in patients 80 years of age and older.

Authors:  Baydar Behlül; Serin Ayfer; Vatansever Sezgin; Kandemir Altay; Celik Mustafa; Cekiç Cem; Ormeci Bilge; Aslan Fatih; Alper Emrah; Buyraç Zafer; Aksöz Kadir; Unsal Belkis
Journal:  Prz Gastroenterol       Date:  2014-09-16

4.  Endoscopic Retrograde Cholangiopancreatography Using a Dual-Lumen Endogastroscope for Patients with Billroth II Gastrectomy.

Authors:  Wei Yao; Yonghui Huang; Hong Chang; Ke Li; Xuebiao Huang
Journal:  Gastroenterol Res Pract       Date:  2013-05-27       Impact factor: 2.260

5.  Pneumoperitoneum after Endoscopic Retrograde Cholangiopancreatography due to Rupture of Intrahepatic Bile Ducts and Glisson's Capsule in Hepatic Metastasis: A Case Report and Review of Literature.

Authors:  Zubair Khan; Umar Darr; Mohamad Nawras; Muhammad Bawany; Jacob Bieszczad; Osama Alaradi; Ali Nawras
Journal:  Case Rep Gastroenterol       Date:  2017-10-06

6.  Prognosis and risk factors of ERCP pancreatitis in elderly.

Authors:  Erhan Ergin; Nevin Oruç; Galip Ersöz; Oktay Tekeşin; Ömer Özütemiz
Journal:  Sci Rep       Date:  2021-08-05       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.